Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein HIV-1 Vaccines (PDPHV-201401) Co-administered With or Without Adjuvant GLA-SE in Repeated Doses, in Healthy, HIV-1 Uninfected Adult Participants

NCT04927585 is registered in ClinicalTrials.gov with Worcester HIV Vaccine as lead sponsor.

NCT NCT04927585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04927585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein HIV-1 Vaccines (PDPHV-201401) Co-administered With or Without Adjuvant GLA-SE in Repeated Doses, in Healthy, HIV-1 Uninfected Adult Participants
Lead sponsor
Worcester HIV Vaccine
Phase
Phase 1
Overall status
Completed
Start date
July 8, 2021
Completion date
December 7, 2023
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections